Cancer Hormone Prostate Therapy

Last year, a groundbreaking international project found that a group of Japanese patients with advanced non-small cell lung cancer survived longer - and had a higher rate of side effects - than U.S. patients with the same diagnosis, when both groups were given two well-known drugs for the disease.

Now, a follow-up study suggests the reasons appear to lie in subtle variations in certain genes that govern how the body metabolizes chemotherapy drugs. David Gandara, M.D., a University of California, Davis researcher who led the recent Southwest Oncology Group study, presented the results at the American Society of Clinical Oncology annual meeting.

The discovery that Japanese and U.S. patients, matched in age, gender and other respects, had differences in key metabolism-related genes is the latest result from a seven-year collaboration between the Southwest Oncology Group and two clinical trials groups in Japan.

Genomic Health, Inc. Announces Oncotype DX(TM) Recurrence Score(TM ...

CHICAGO, June 2 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results of an independent prospective multi-center study indicating that the Oncotype DX Recurrence Score changes treatment decisions and increases confidence for a high proportion of patients with early-stage node-negative, estrogen receptor-positive breast cancer. Results from this study were presented today at the 43rd annual meeting of the American Society of Clinical Oncology (Abstract #577).

In a study of 89 patients treated by 17 medical oncologists from three academic and one community practice, knowledge of a patient's Recurrence Score changed treatment recommendations and decisions for 31.5 percent of oncologists and 27 percent of patients, respectively. The most common change was to switch from a plan for chemotherapy plus hormonal therapy before receiving Recurrence Score results to hormonal therapy alone after a low Recurrence Score result was obtained.

Advanced Life Sciences Announces Supplemental Efficacy Data from ...

CHICAGO, July 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced the confirmation of supplemental efficacy data from Trial CL-06, the first of two pivotal Phase 3 clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day antibiotic, for the treatment of community acquired pneumonia (CAP). The Company also provided an update to the projected timeline for announcement of top-line data from the second CAP study, Trial CL-05.

The Company is hosting a conference call and live webcast at 10:00 am (EDT) today, July 2, 2007 to discuss the available data from Trial CL-06. On the call will be members of the Advanced Life Sciences management team along with Donald E.